News >

Clearing Up Confusion on Cytoreductive Nephrectomy in mRCC

Caroline Seymour
Published: Monday, Aug 19, 2019

David D. Thiel, MD

David D. Thiel, MD

The decision of whether or not to recommend cytoreductive nephrectomy to patients with metastatic renal cell carcinoma (mRCC) is much more nuanced than the topline findings of the phase III CARMENA trial suggest, said David D. Thiel, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication